RLMD vs ALTO vs AXSM vs REX vs INVA

For growth investors, Axsome Therapeutics, Inc.

(AXSM) is the stronger pick with 65. 5% revenue growth year-over-year, versus -22. 9% for REX American Resources Corporation (REX). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Relmada Therapeutics, Inc. (RLMD) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus REX American Resources Corporation at 29. 5x. On forward P/E, Innoviva, Inc. is actually cheaper at 11. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innoviva, Inc. wins at 1. 15x versus REX American Resources Corporation's 1. 18x — a reasonable growth-adjusted valuation.

Over the past 5 years, Axsome Therapeutics, Inc.

(AXSM) delivered a total return of +286. 4%, compared to -21. 2% for Alto Ingredients, Inc. (ALTO). Over 10 years, the gap is even starker: AXSM returned +1886% versus ALTO's +6. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Relmada Therapeutics, Inc. 's 1. 40β — meaning RLMD is approximately 1011% more volatile than INVA relative to the S&P 500. On balance sheet safety, REX American Resources Corporation (REX) carries a lower debt/equity ratio of 3% versus 3% for Axsome Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Axsome Therapeutics, Inc.

(AXSM) is pulling ahead at 65. 5% versus -22. 9% for REX American Resources Corporation (REX). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -4. 9% for REX American Resources Corporation. Over a 3-year CAGR, AXSM leads at 133. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -28. 7% for Axsome Therapeutics, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -26. 5% for AXSM. At the gross margin level — before operating expenses — AXSM leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Innoviva, Inc. (INVA) is the more undervalued stock at a PEG of 1. 15x versus REX American Resources Corporation's 1. 18x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Innoviva, Inc. (INVA) trades at 11. 9x forward P/E versus 62. 8x for REX American Resources Corporation — 50. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 65. 2% to $37. 67.

In this comparison, ALTO (0.

4% yield) pays a dividend. RLMD, AXSM, REX, INVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Axsome Therapeutics, Inc.

(AXSM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 69), +1886% 10Y return). Both have compounded well over 10 years (AXSM: +1886%, RLMD: +312. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RLMD (Healthcare) and ALTO (Basic Materials) and AXSM (Healthcare) and REX (Basic Materials) and INVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RLMD is a small-cap quality compounder stock; ALTO is a small-cap quality compounder stock; AXSM is a mid-cap high-growth stock; REX is a small-cap quality compounder stock; INVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.